deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00229619

Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia

A Pilot Study of Recombinant Humanized Anti- Cluster of Differentiation Antigen 20 (Anti-CD20) Antibody (Rituximab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Conditions Anemia, Aplastic Anemia, Diamond-Blackfan Red-Cell Aplasia, Pure
Interventions Rituximab
Updated 9 times since 2017 Last updated: Aug 20, 2018 Started: Sep 30, 2005 Primary completion: Jun 30, 2010 Completion: Jun 30, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00229619, this PHASE2 trial focuses on Anemia, Aplastic and Anemia, Diamond-Blackfan and remains completed. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 9 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshotCompleted~Oct 2018 – ~Jan 2021 · 27 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotCompleted~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  5. Dec 2021 — Dec 2022 [monthly]

    Completed PHASE2

▶ Show 4 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2

  2. Oct 2018 — Jan 2021 [monthly]

    Completed PHASE2

  3. Jun 2018 — Oct 2018 [monthly]

    Completed PHASE2

  4. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Heart, Lung, and Blood Institute (NHLBI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations